We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mylan yesterday confirmed that it had settled its claims against drugmakers Akzo Nobel and Organon over Organon’s alleged anticompetitive actions to delay generic competition on its depression drug Remeron.
The AARP has filed an amicus brief supporting generic drugmaker Teva Pharmaceuticals’ bid to get a federal district court to hear its patent challenge against Pfizer’s lucrative antidepressant Zoloft (sertraline HCl).
The FDA received legal papers late Wednesday from generic firm Apotex regarding the agency’s decision to grant 180 days of market exclusivity for a version of Pfizer’s epilepsy drug Neurontin (gabapentin) to one generic firm, said FDA Chief Counsel Dan Troy yesterday during the Food and Drug Law Institute’s annual conference in Washington, D.C.
Generic drugmaker Teva Pharmaceuticals has picked up another major ally in its bid to convince a federal district court to hear its patent challenge against Pfizer’s lucrative antidepressant Zoloft (sertraline HCl).
Dental care drugmaker CollaGenex Pharmaceuticals and generic firm Mutual Pharmaceuticals have settled a patent infringement suit over CollaGenex’s gum disease drug Periostat.
An argument by Novartis that the physiological interaction between a competitor’s cyclosporine product and a patient’s body infringed on one of its patents has been rejected by a federal appeals court.
The FTC is urging a federal appeals court to reverse a lower court’s dismissal of generic firm Teva Pharmaceutical’s filing challenging the validity of Pfizer’s patent for the antidepressant Zoloft (sertraline HCl) in a case that could clarify the controversial declaratory judgment provision of last year’s drug patent law.
In a case that could clarify the controversial declaratory judgment provision of last year’s drug patent law, the FTC is urging a federal appeals court to reverse a lower court’s dismissal of generic firm Teva Pharmaceutical’s filing challenging the validity of Pfizer’s patent for the antidepressant Zoloft (sertraline HCl).
Barr Pharmaceuticals is facing its fourth patent infringement lawsuit by Kos Pharmaceuticals over the Barr’s bid to market a generic version of Kos’ cholesterol drug Niaspan (niacin).